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c A s E  r E P O r t
We present a case of a 57-year-old man, with a history of heavy smoking, non-
insulin dependent diabetes mellitus (NIDDM) and untreated hypercholesterolemia. 
He was complaining for typical angina on effort which started one month ago. He had 
a treadmill stress test which was terminated very early because of angina and ECG 
changes evident of myocardial ischemia. 
Coronary angiogram showed diffuse disease of the right coronary artery (RCA) 
and 100% obstruction (Fig. 1), a non significant plaque at the distal part of left main 
coronary artery, diffuse disease in the left anterior descending (LAD) and left circum-
flex (LCx) (Fig. 2 & 3) with very significant and complex lesions at the proximal parts, 
and left ventricular ejection fraction impaired, estimated about 35%. We proposed 
that according to the evidence and the guidelines he should have surgery (CABG). 
Although we insisted on CABG, the patient rejected this treatment and asked for 
coronary angioplasty (PTCA). 
We planned a two-stage procedure which included a first attempt to recanalize 
the RCA total occlusion and, if successful, then proceed with full revascularization, 
stenting only the ostia and the proximal parts of LAD and LCx. We also scheduled 
to use intravascular ultrasound (IVUS) in the left coronary artery in order to define 
vessel diameter, so that a stent of larger diameter could be implanted, and clarify about 
involvement of the left main.
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The RCA was approached with a guiding catheter Judkins 
Right 3.5 6F. We used an over the wire balloon (Maverick 
1.5X10mm) with a Whisper guidewire, crossing the total 
occlusion and reaching at the most distal part of the vessel. 
As the Maverick balloon could not be delivered distally, we 
exchanged for a monorail balloon Riujin 1.25x15 mm and we 
performed 3 inflations at 14 atm, thus restoring flow at the 
part of RCA after the total occlusion. We then used larger 
balloons (Sequent) 2x15mm and 2.5x10mm to prepare the ves-
sel for total reconstruction. We decided to cover all the vessel 
from the ostium to the mid part and leaving the distal part 
before the crux diffusely diseased with good flow, and thus we 
implanted two overlapping stents Cypher Select plus 3x28 mm 
and 3x33 mm (at 14 atm) with a very good result. Subsequently, 
we changed strategy and decided to cover the distal part as 
well, but a Cypher Select plus 2.75x18 mm stent could not be 
delivered, although we post-dilated with a Maverick 3.5x18 
mm balloon. Finally, we managed to deliver and implant 3 
XScience stents overlapped (3x18 mm, 3x15 mm, 3x12 mm) 
at 14 atm, with a very good final result (Fig. 4). Tirofiban was 
administered during and after the procedure.
Five days later the patient came back for the second part 
of the staged procedure. We used an EBU 3.5 7F guiding 
catheter and the LAD, LCx and the intermediate vessel were 
all wired with Whisper guidewires. First, we used a Riujin 
2x15 mm balloon, and then a Sequent 2.5x15 mm balloon to 
prepare the lesions of the LAD from the ostium to the mid 
part of the vessel resulting in good flow. An IVUS run in the 
LAD was then performed which demonstrated a medium size 
vessel (about 3 mm in diameter), with a lot of calcium and an 
atheromatic plaque at the distal part of the left main which did 
not cause significant stenosis (area=8.6 mm2). A Taxus Liberte 
2.75x28 mm stent was implanted in the mid part of the LAD, 
and another overlapping stent Taxus Liberte 3x32 mm could 
be delivered only after preparing the proximal LAD with a 
cutting balloon 3x10mm (at 12 atm) with a very good result. 
Then, we predilated the long lesion in the proximal LCx with 
a Sequent 2.5x10 mm and a Maverick 3X12 mm balloon, and 
we implanted two overlapping stents Taxus Liberte 2.75x16 mm 
and 3x16 mm (at 14 atm) with a very good result. The procedure 
ended with simple balloon angioplasty at the proximal lesion 
of the intermediate branch with a Maverick 3x12mm balloon 
with an acceptable result (Fig. 5 & 6). Tirofiban was infused 
during and after the procedure.
Totally, we treated 7 lesions in 3 vessels, using  DES and 
covering a total length of 18 mm. In one year follow up, the 
patient has not had any symptoms, has modified all risks factors 
(LDL=46 mg/dl, HbA1c=6.2%) and is in a very good physical 
condition. He has been submitted to dobutamine stress echo 
with contrast twice, reaching cardiac frequency 154/min which 
proved to be negative for myocardial ischemia. 
D I s c U s s I O N 
The optimal therapeutic strategy for multi-vessel coronary 
artery disease still remains a controversial issue. coronary 
artery bypass grafting (CABG) has long been the defini-
tive, but aggressive therapeutic strategy for the treatment of 
patients with multi-vessel coronary artery disease. However, 
much progress in interventional cardiology has expanded its 
application from treating single, simple lesions to multiple 
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and severely complex stenoses. Early trials [1-3] comparing 
percutaneous coronary intervention (PCI) with bare metal 
stent implantation and revascularization with cABG had 
raised an optimistic perspective regarding the efficacy of PCI 
in long-term results since no differences in terms of mortality 
and myocardial infarction had been identified. However, the 
CABG arm had been found superior to PCI regarding repeat 
revascularization and long-term relief from angina.
Four large multi-centre, randomized studies were con-
ducted in the 10s to compare bare metal stent implantation 
with CABG in patients with multivessel disease: AWESOME 
[4], ERACI II [5,6], SOS [7] and ARTS [8,]. The Angina With 
Extremely Serious Operative Mortality Evaluation (AWE-
SOME) trial [4] was one of the first randomized, multi-center 
studies that did not identify statistical significant difference in 
the global survival or survival free of unstable angina among 
patients with multi-vessel disease treated with CABG or PCI 
with stent implantation in three years’ follow up. Paradoxically, 
repeat revascularizations were observed to be generally greater 
in the surgical group than in the PCI group.
The ERACI II study (Argentine Randomised Study: 
Coronary angioplasty with stenting vs. coronary bypass surgery 
in multi-vessel disease) [5,6] included 450 patients and demon-
strated better survival and freedom from myocardial infarction 
in the PCI arm compared with the surgical group during the 
first 30 days post-procedurally, when more patients died in 
the surgical group, but disappeared after one month. CABG 
in-hospital mortality in the ERACI II study was higher than 
in other trials, but was mainly observed in patients with severe 
unstable angina. Moreover, revascularization procedures and 
major adverse cardiovascular events were significantly less in 
the group of CABG.
The SoS (Stent or Surgery) trial [7] was conducted in 53 
centers in Europe and Canada and 88 patients were rand-
omized. The incidence of death or non-fatal Q-wave myo-
cardial infarction was similar in both groups but survival was 
significantly lower in the PCI arm which was however mainly 
attributed to the increased rate of cancer-related deaths.
The Arterial Revascularisation Therapies Study (ARTS) 
[8,] was designed to compare CABG and stenting in patients 
with multi-vessel disease. In total, 1205 patients from 67 par-
ticipating centers were randomized to either stent implantation 
or CABG. Overall survival, stroke, or myocardial infarction 
was not significantly different between PCI and CABG groups 
in 1 and 5 years follow-up. However, repeat revascularization 
was found significantly higher in the PCI group than in the 
CABG group.
A recent meta-analysis [10] of the these four studies 
confirmed that patients with multi-vessel disease undergoing 
surgical revascularization or stent implantation were protected 
against death, myocardial infarction, or stroke to a similar 
degree. In contrast, repeat revascularization procedures were 
higher in the PCI group. 
Drug-eluting stents (DES) seem to overcome the disad-
vantages that restrict the unlimited use of bare metal stents. 
Non-randomized studies and registries have shown promising 
results regarding high-risk populations with complex lesions 
[11,12]. However, concerns have been raised recently regard-
ing the long-term safety of DES, as a consequence of the 
reported potentially increased risk of late thrombosis [13,14]. 
Therefore, revascularization with DES should be compared 
with CABG in new large-scale, randomized trials which will 
enroll high risk patients.
ARTS II (Arterial Revascularisation Therapies Study 
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II) [15] compared the effectiveness of sirolimus-eluting stent 
implantation with the historical two arms of ARTS.  ARTS 
II enrolled 607 patients (53.5% with 3-vessel disease) from 
45 centers. The composite major adverse cardiac and cardio-
vascular events at one year follow up were low (10.5%) and 
were comparable as the historical surgical arm of ARTS. 
Although the re-intervention rates in the drug-eluting stents 
group were still higher than those of the CABG group, this was 
counter-balanced by a higher incidence of death / stroke and 
myocardial infarction. Moreover, diabetic patients in the DES 
group had a twofold greater need for repeat revascularization 
in the first year as compared to non-diabetic patients, although 
having lower event rates than those in the bare metal group.
The SYNTAX trial (SYNergy between percutaneous 
coronary intervention with TAXus and cardiac surgery) [16] 
is a multi-center, randomized study, designed to evaluate 
the optimum revascularization treatment for patients with 
de novo 3-vessel disease and/or left main disease (either iso-
lated or with 1-, 2-, or 3-vessel disease). In this study patients 
are randomized to either PCI with paclitaxel-eluting stents 
or surgery, only if PCI and CABG can achieve comparable 
revascularization as judged by a local heart team consisting 
of an interventional cardiologist, cardiothoracic surgeon 
and study coordinator. The excluded patients are enrolled 
and follow-up in the Registry Arm. A total of 1500 patients 
have been randomized from 0 centers in Europe and in the 
USA. The primary endpoint is freedom from major adverse 
cardiac and cerebral events at one year. The CABG registry 
will determine the high-risk subsets that are not suitable for 
PCI, whereas the PCI registry may define the population for 
which CABG is inappropriate. 
The FREEDOM multi-centre trial will randomize 2400 
diabetic patients with 2- or 3-vessel disease to either surgical 
or percutaneous revascularization with DES. The study will 
be conducted in North America and Europe and the primary 
endpoint is mortality at 5 years.
The CARDia (Coronary Artery Revascularisation in Dia-
betes) trial [17] is conducted in the UK and Ireland and will 
randomize 600 diabetic patients with either complex one-vessel 
disease or multi-vessel disease to CABG or PCI. The primary 
endpoint is the composite incidence of death, non-fatal myo-
cardial infarction or non-fatal stroke at one year. 
The promising results demonstrated in small-scale studies 
and registries suggest that DES may abolish the limitations 
encountered with bare metal stent implantation. The results of 
SYNTAX, FREEDOM and CARDia are expected with great 
interest and will probably expand the indications for PCI in 
more complex and high-risk lesions. According to the current 
guidelines, patients with three-vessel disease with impaired 
ejection fraction and presence of diabetes mellitus must be 
treated with CABG. However, there are exceptions, such as 
diffuse disease, contra-indications to CABG and patient’s 
wish, where PTCA is a very good alternative. In 3-vessel dif-
fuse disease, CABG is not superior to PTCA with DES. In 
order to avoid excess length of DES, we think that it is wise 
to open the proximal-mid parts of all three vessels and leave 
the distal parts as they are if the flow is TIMI 3, just as the 
surgeon would do so for sure. 
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